Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis - Top-Institutions - MDSpire

Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis

  • By

  • Xinyuan Cui

  • Mengru Yuan

  • Yanting Mao

  • Bojin Xu

  • Haiping Zhou

  • Shan Huang

  • Wenfang Peng

  • May 18, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Tongren Hospital
    Tongren Hospital

    Beijing, China

    Key Differentiators

    • Endocrinology

  • #2

    Shanghai Jiao Tong University School of Medicine
    Shanghai Jiao Tong University School of Medicine

    Shanghai, China

    Key Differentiators

    • Endocrinology

  • #3

    PHARMO Database Network
    PHARMO Database Network

    Utrecht, Netherlands

    Key Differentiators

    • Epidemiology

  • #4

    Netherlands Cancer Registry (NCR)
    Netherlands Cancer Registry (NCR)

    Utrecht, Netherlands

    Key Differentiators

    • Oncology

  • #5

    Netherlands Comprehensive Cancer Organization (IKNL)
    Netherlands Comprehensive Cancer Organization (IKNL)

    Utrecht, Netherlands

    Key Differentiators

    • Oncology

Original Source(s)

Association between the composite CRP–TyG index and incident malignancy risk in hospitalized patients with diabetes: a retrospective cohort study with nonlinear effect analysis

  • by Xinyuan Cui, Mengru Yuan, Yanting Mao, Bojin Xu, Haiping Zhou, Shan Huang, Wenfang Peng

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...